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ABSTRACT 
Background: Hemangiopericytomas (HPCs) and solitary fibrous tumours (SFTs) of the 
Central Nervous System (CNS) were classified as two distinct entities under meningeal 
based tumors in the 2007 WHO classification of tumors of the Central Nervous System.  
As both HPCs and SFTs of soft tissue have been found to share certain genetic 
alterations, these two tumors are now considered part of a single spectrum in soft tissue 
and as of 2016, also in the CNS. STAT6 and more recently GRIA2 have been reported as 
useful markers to identify these neoplasms. 
The purpose of the present study was to carry out a detailed histological and 
immunohistochemical study of HPCs and SFTs of the CNS and to study the expression 
profile of STAT6 and GRIA2 in these tumors. The study also aimed to test the diagnostic 
capability of these two markers to differentiate HPCs/SFTs from their close histological 
and topographic mimics, meningiomas. 
Methods: A detailed histological study of 75 HPCs and SFTs, reported between 1990 
and 2014 was carried out. Immunohistochemistry was performed on these cases using 
rabbit monoclonal antibodies to STAT6 and GRIA2 A tissue microarray of 176 cases of 
meningiomas that served as a control, was also subjected to immunohistochemistry for 
STAT6 and GRIA2.  
Results: There were 65 (86.66%) HPCs and 10 (13.33%) SFTs in the study population, 
which included 32 HPC WHO Grade II and 33 HPC WHO Grade III. The mean age at 
diagnosis of HPCs was 38 years and that of SFTs 45 years. Both HPCs and SFTs had a 
male preponderance with a M: F ratio of 1.32: 1 and 2.3: 1, respectively. The 
predominant architectural pattern in HPCs was of patternless sheets whilst in SFTs it was 
interlacing fascicles. Stromal collagen was seen in 90% of SFTs and in only 9% of the 
HPCs. Diffuse hypercellularity and nuclear pleomorphism were features almost exclusive 
to HPCs with hypercellularity seen only focally in 10% of SFTs. The mean mitotic count 
of SFTs was 1.5/10 HPF, whilst in HPCs, the mean mitotic count was 1.97/10 HPF for 
WHO Grade II HPCs and, 7.97/10 HPF for WHO Grade III HPCs. Nuclear 
immunopositivity for STAT6 was seen in 89.2% of HPCs, 80% of SFTs and none of the 
meningiomas. STAT6 immunohistochemistry had a sensitivity of 88% and a specificity 
of 100% for the diagnosis of SFT/HPC. Cytoplasmic immunopositivity for GRIA2 was 
seen in 98.5% of HPCs, 100% of SFTs and 96.5 % of the meningiomas. GRIA2 
immunohistochemistry had a sensitivity of 98.7% with a specificity of 3.5% for the 
diagnosis of SFT/HPC. 
Conclusion: Since a high proportion of both HPCs and SFTs showed nuclear 
immunoreactivity for STAT6, the present study supports the merging of these two 
entities as one. The high specificity of STAT6 immunohistochemistry in diagnosing 
SFT/HPC makes it a useful marker to differentiate it from other dural based tumors such 
as meningiomas. On the other hand, GRIA2 with its low specificity is a poor marker for 
diagnosing SFT/HPC. 
 
 
